AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12689742 — intervention group
Group type: EXPERIMENTAL
Intervention: Personally tailored workbook and telephone counseling program
Number of subjects: 420
Study 10606361 — intervention group
Group type: EXPERIMENTAL
Intervention: Synacthen depot 0.5 mg on alternate days for 2 injections
Number of subjects: 36
Study 10606361 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 36
Study 10606361 — intervention group
Group type: EXPERIMENTAL
Intervention: Synacthen depot
Number of subjects: 36
Study 7594164 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral/educational intervention for urinary incontinence
Number of subjects: 101
Study 7594164 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 101
Study 2840279 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar biscuit (2.9 g of guar)
Number of subjects: 8
Study 2840279 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar biscuit (6.0 g of guar)
Number of subjects: 8
Study 2840279 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar biscuit (9.1 g of guar)
Number of subjects: 8
Study 2840279 — intervention group
Group type: COMPARATOR
Intervention: Control biscuit
Number of subjects: 8
Study 31865336 — intervention group
Group type: EXPERIMENTAL
Intervention: CTA membrane
Number of subjects: 15
Study 31865336 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyamide membrane
Number of subjects: 15
Study 31865336 — intervention group
Group type: EXPERIMENTAL
Intervention: Polynephron membrane
Number of subjects: 15
Study 31865336 — intervention group
Group type: EXPERIMENTAL
Intervention: Helixone membrane
Number of subjects: 15
Study 31600472 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocabulary training on Vocabulary.com for a minimum of 20 min, 4 times per week for 4 weeks (total 320 min).
Number of subjects: 40
Study 31600472 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocabulary training on Vocabulary.com
Number of subjects: 40
Study 31600472 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 40
Study 28392018 — intervention group
Group type: EXPERIMENTAL
Intervention: SET curriculum training
Number of subjects: 20
Study 25586983 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital storytelling intervention (n=15)
Number of subjects: 28
Study 25586983 — intervention group
Group type: COMPARATOR
Intervention: Customary care (Control group, n=13)
Number of subjects: 28
Study 23218136 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (60 min of walking at 60% peak oxygen uptake)
Number of subjects: 13
Study 23218136 — intervention group
Group type: COMPARATOR
Intervention: Control (inactive)
Number of subjects: 13
Study 21196070 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated AutoPulse-CPR (iA-CPR)
Number of subjects: 0
Study 21196070 — intervention group
Group type: COMPARATOR
Intervention: Manual CPR (M-CPR)
Number of subjects: 0
Study 18435370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nite White Excel 2Z
Number of subjects: 46
Study 18435370 — intervention group
Group type: EXPERIMENTAL
Intervention: Rembrandt Xtra Comfort
Number of subjects: 46
Study 21878067 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q(10) in combination with enalapril
Number of subjects: 0
Study 16152867 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Number of subjects: 49
Study 16152867 — intervention group
Group type: COMPARATOR
Intervention: Control group (other methods of pain control)
Number of subjects: 49
Study 11898915 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive SLE patients (group I, no IT); PPD1 = 8.4 +/- 2.3
Number of subjects: 145
Study 11898915 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive SLE patients (group II, with IT); PPD1 = 5.1 +/- 1.9
Number of subjects: 145
Study 11898915 — intervention group
Group type: EXPERIMENTAL
Intervention: Active SLE patients (group III, no IT); PPD1 = 1.4 +/- 0.9
Number of subjects: 145
Study 11898915 — intervention group
Group type: EXPERIMENTAL
Intervention: Active SLE patients (group IV, with IT); PPD1 = 0.6 +/- 0.5
Number of subjects: 145
Study 11898915 — intervention group
Group type: COMPARATOR
Intervention: Controls; PPD1 = 9.4 +/- 3
Number of subjects: 145
Study 11898915 — intervention group
Group type: EXPERIMENTAL
Intervention: Group IV (active with IT); PPD2 = 0.3 +/- 0.3
Number of subjects: 145
Study 11898915 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (inactive no IT); PPD2 = 2.6 +/- 0.9
Number of subjects: 145
Study 11898915 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (inactive with IT); PPD2 = 3.1 +/- 0.8
Number of subjects: 145
Study 11898915 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (active no IT); PPD2 = 1.2 +/- 0.8
Number of subjects: 145
Study 11898915 — intervention group
Group type: COMPARATOR
Intervention: Controls; PPD2 = 7.9 +/- 2.5
Number of subjects: 145
Study 9674789 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine 10 mg
Number of subjects: 25
Study 9674789 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine 20 mg
Number of subjects: 25
Study 9674789 — intervention group
Group type: COMPARATOR
Intervention: Midodrine (2.5, 10, or 20 mg)
Number of subjects: 25
Study 8072201 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy followed by surgery
Number of subjects: 95
Study 8072201 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy followed by irradiation
Number of subjects: 95
Study 3239478 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper IUDs (non-complicated use)
Number of subjects: 600
Study 3239478 — intervention group
Group type: COMPARATOR
Intervention: Copper IUDs (complicated use)
Number of subjects: 600
Study 12525260 — intervention group
Group type: EXPERIMENTAL
Intervention: Maca 1500 mg
Number of subjects: 100
Study 12525260 — intervention group
Group type: EXPERIMENTAL
Intervention: Maca 3000 mg
Number of subjects: 100
Study 12525260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30583542 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean-burning liquefied petroleum gas (LPG) stove
Number of subjects: 0
Study 30583542 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 27990507 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mm-long implants
Number of subjects: 80
Study 27990507 — intervention group
Group type: COMPARATOR
Intervention: 10 mm or longer implants in augmented bone
Number of subjects: 80
Study 27990507 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants (4.0 mm)
Number of subjects: 80
Study 27990507 — intervention group
Group type: COMPARATOR
Intervention: 10 mm or longer mandibular implants
Number of subjects: 80
Study 27990507 — intervention group
Group type: EXPERIMENTAL
Intervention: Short maxillary implants
Number of subjects: 80
Study 27990507 — intervention group
Group type: COMPARATOR
Intervention: 10 mm or longer maxillary implants
Number of subjects: 80
Study 27990507 — intervention group
Group type: COMPARATOR
Intervention: Augmented group (10 mm or longer implants)
Number of subjects: 80
Study 24588456 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic needle tip positioning technique
Number of subjects: 40
Study 24588456 — intervention group
Group type: COMPARATOR
Intervention: Traditional palpation technique
Number of subjects: 40
Study 23327881 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac) administered once daily at a dose of 3 mg
Number of subjects: 19
Study 20494927 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones
Number of subjects: 2745
Study 18076881 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz electroacupuncture (EA) stimulation of ST-29 (guilai)
Number of subjects: 80
Study 18076881 — intervention group
Group type: COMPARATOR
Intervention: Simple needle insertion
Number of subjects: 80
Study 18076881 — intervention group
Group type: COMPARATOR
Intervention: 2-Hz burst EA stimulation
Number of subjects: 80
Study 18076881 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz EA stimulation of ST-25 (tianshu)
Number of subjects: 80
Study 16189764 — intervention group
Group type: EXPERIMENTAL
Intervention: HRE-ICC
Number of subjects: 28
Study 16189764 — intervention group
Group type: EXPERIMENTAL
Intervention: HRE-NBI
Number of subjects: 28
Study 16189764 — intervention group
Group type: COMPARATOR
Intervention: HRE alone
Number of subjects: 28
Study 16189764 — intervention group
Group type: COMPARATOR
Intervention: Random biopsies
Number of subjects: 28
Study 11823664 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (biweekly intravenous alpha-galactosidase A infusions)
Number of subjects: 26
Study 11823664 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (placebo)
Number of subjects: 26
Study 10369625 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily aminoglycosides (ODA)
Number of subjects: 0
Study 10369625 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosing of aminoglycosides
Number of subjects: 0
Study 7771004 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 monotherapy (20 micrograms)
Number of subjects: 22
Study 7771004 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Prostaglandin E1 20 micrograms plus lidocaine 1% 1 cc)
Number of subjects: 22
Study 2335312 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction with oxytocin infusion
Number of subjects: 93
Study 2335312 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 93
Study 387172 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamgee‐lined hat
Number of subjects: 211
Study 387172 — intervention group
Group type: COMPARATOR
Intervention: No hat (Control)
Number of subjects: 211
Study 31403668 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based HIV/STD risk reduction intervention
Number of subjects: 219
Study 31403668 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 219
Study 30468951 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic compression stockings (ECS) continued after one year
Number of subjects: 0
Study 30468951 — intervention group
Group type: COMPARATOR
Intervention: Elastic compression stockings (ECS) discontinued after one year
Number of subjects: 0
Study 28040237 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum Elastic Bougie (GEB)
Number of subjects: 134
Study 28040237 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscopy (NI)
Number of subjects: 134
Study 28040237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 134
Study 26336604 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (QIV)
Number of subjects: 601
Study 26336604 — intervention group
Group type: COMPARATOR
Intervention: Trivalent control vaccine (TIV)
Number of subjects: 601
Study 23843881 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied at local acupoints on the affected wrist (PC‐7 to TW‐5)
Number of subjects: 0
Study 23843881 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at distal acupoints (contralateral ankle, SP‐6 to LV‐4)
Number of subjects: 0
Study 23843881 — intervention group
Group type: COMPARATOR
Intervention: Sham EA at nonacupoint locations on the affected wrist
Number of subjects: 0
Study 21329513 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone consultations with complementing text-messages
Number of subjects: 0
Study 21329513 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular patient-individual telephone consultations
Number of subjects: 0
Study 18952082 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 127
Study 17239945 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite (Sinfony, 3M‐ESPE)
Number of subjects: 7
Study 17239945 — intervention group
Group type: COMPARATOR
Intervention: Ceramic (negative control)
Number of subjects: 7
Study 17239945 — intervention group
Group type: COMPARATOR
Intervention: Unfilled resin (positive control)
Number of subjects: 7
Study 12714402 — intervention group
Group type: EXPERIMENTAL
Intervention: Unoprostone isopropyl 0.15%
Number of subjects: 146
Study 12714402 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 146
Study 12714402 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide hydrochloride 2.0%
Number of subjects: 146
Study 11213534 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 1936
Study 11213534 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 1936
Study 8615362 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistant starch (39 +/- 3 g/d)
Number of subjects: 11
Study 8615362 — intervention group
Group type: COMPARATOR
Intervention: Low-resistant starch (5 +/- 0.4 g/d)
Number of subjects: 11
Study 1351126 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-RG (group C, 10(5.5) tissue-culture infectious doses50)
Number of subjects: 25
Study 1351126 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-RG (group B, 10(4.5) tissue-culture infectious doses50)
Number of subjects: 25
Study 1351126 — intervention group
Group type: COMPARATOR
Intervention: HDC (6.52 international potency units per dose)
Number of subjects: 25
Study 1351126 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-RG and HDC
Number of subjects: 25
Study 3969876 — intervention group
Group type: EXPERIMENTAL
Intervention: Bretylium 2.5 mg/kg over 60 minutes
Number of subjects: 6
Study 3969876 — intervention group
Group type: EXPERIMENTAL
Intervention: Bretylium 5.0 mg/kg over 60 minutes
Number of subjects: 6
Study 3969876 — intervention group
Group type: EXPERIMENTAL
Intervention: Bretylium 10 mg/kg over 60 minutes
Number of subjects: 6
Study 3969876 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6
Study 29961346 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centred activities of daily living (CADL) intervention
Number of subjects: 10
Study 30938654 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mini-implants
Number of subjects: 120
Study 30938654 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mini-implants
Number of subjects: 120
Study 30938654 — intervention group
Group type: COMPARATOR
Intervention: 2 standard implants
Number of subjects: 120
Study 26773737 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (Blood Pressure Education Program [BPEP])
Number of subjects: 137
Study 26773737 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined program (COMBO)
Number of subjects: 137
Study 26773737 — intervention group
Group type: COMPARATOR
Intervention: Blood Pressure Education Program (BPEP)
Number of subjects: 137
Study 26773737 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 137
Study 26773737 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga and BPEP combined
Number of subjects: 137
Study 24690964 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (2.5 g per day of eicosapentaenoic + docosahexaenoic)
Number of subjects: 78
Study 24690964 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil ethyl esters)
Number of subjects: 78
Study 22472515 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (1,100 ppm F as NaF), 0.12% chlorhexidine gluconate rinse, and 0.05% NaF rinse
Number of subjects: 231
Study 22472515 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 231
Study 22472515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 231
Study 20152959 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free diclofenac sodium 0.1% (Voltaren ophtha SDU; Novartis Pharma)
Number of subjects: 102
Study 20152959 — intervention group
Group type: COMPARATOR
Intervention: Preserved diclofenac sodium 0.1% (Voltaren ophtha; Novartis Pharma)
Number of subjects: 102
Study 20152959 — intervention group
Group type: COMPARATOR
Intervention: Preserved ketorolac tromethamine 0.5% (Acular; Pharm Allergan)
Number of subjects: 102
Study 17661245 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning preparation
Number of subjects: 201
Study 17661245 — intervention group
Group type: COMPARATOR
Intervention: Evening preparation
Number of subjects: 201
Study 16128276 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically derived vaccine (20 microg)
Number of subjects: 40
Study 16128276 — intervention group
Group type: COMPARATOR
Intervention: Plasma pooled vaccine (3 microg)
Number of subjects: 40
Study 12383815 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold infrared (810 nm) diode laser macular grid photocoagulation
Number of subjects: 50
Study 12383815 — intervention group
Group type: COMPARATOR
Intervention: Observation (no treatment)
Number of subjects: 50
Study 9846796 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.12%) and Perborate (1.9 g sodium perborate-monohydrate in 30 ml water)
Number of subjects: 12
Study 9846796 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (0.12%)
Number of subjects: 12
Study 8003060 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline for 30 days
Number of subjects: 38
Study 8003060 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin plus probenecid for 30 days
Number of subjects: 38
Study 8003060 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone for 2 weeks
Number of subjects: 38
Study 2553364 — intervention group
Group type: EXPERIMENTAL
Intervention: UFTM (UFT and mitomycin C); UFT: 30 g total dose, Mitomycin C: 48-60 mg total dose
Number of subjects: 140
Study 2553364 — intervention group
Group type: COMPARATOR
Intervention: UFT alone (control)
Number of subjects: 140
Study 794022 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine calcium metrizoate
Number of subjects: 139
Study 794022 — intervention group
Group type: COMPARATOR
Intervention: Meglumine sodium diatrizoate
Number of subjects: 139
Study 794022 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine diatrizoate
Number of subjects: 139
Study 30650418 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care intervention (monthly intervention by palliative care specialists at home for 12 months)
Number of subjects: 49
Study 30650418 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 49
Study 28235493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided subcostal TAP block with 1.5mg/kg bupivacaine diluted with saline to a total volume of 40mL
Number of subjects: 50
Study 28235493 — intervention group
Group type: COMPARATOR
Intervention: No TAP block (Control Group 2)
Number of subjects: 50
Study 28235493 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided subcostal TAP block
Number of subjects: 50
Study 27931247 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete mesocolic excision (CME)
Number of subjects: 1072
Study 27931247 — intervention group
Group type: COMPARATOR
Intervention: D2 dissection
Number of subjects: 1072
Study 24743295 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-initiated HIV testing and counselling (PITC)
Number of subjects: 1772
Study 21859900 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (AC) with gemcitabine 1000 mg/m² on days 1, 8, and 15 and cisplatin 70 mg/m² on day 2, every 28 days.
Number of subjects: 194
Study 21859900 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (AC) with gemcitabine and cisplatin as above.
Number of subjects: 194
Study 21859900 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery alone).
Number of subjects: 194
Study 21859900 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (AC) with cisplatin on day 2.
Number of subjects: 194
Study 21859900 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AC and control groups.
Number of subjects: 194
Study 19111629 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride
Number of subjects: 0
Study 19111629 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 0
Study 17894896 — intervention group
Group type: EXPERIMENTAL
Intervention: >= 101% increment of serum creatinine
Number of subjects: 646
Study 15334421 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET scan in patients with FMS
Number of subjects: 12
Study 15334421 — intervention group
Group type: COMPARATOR
Intervention: FDG-PET scan in healthy controls
Number of subjects: 12
Study 11473839 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine (6 to 10 mL of 0.25% bupivacaine epidurally, followed by infusion at 3 to 5 mL/h for 3 days)
Number of subjects: 50
Study 11473839 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine (2 to 3 mg morphine epidurally, followed by infusion at a rate of 0.2 mg/h)
Number of subjects: 50
Study 9892913 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbinafine 250 mg once daily for 1 week
Number of subjects: 269
Study 9892913 — intervention group
Group type: COMPARATOR
Intervention: 1% clotrimazole cream applied twice daily for 4 weeks
Number of subjects: 269
Study 7996316 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-retaining retractor
Number of subjects: 213
Study 7996316 — intervention group
Group type: COMPARATOR
Intervention: No retractor (control group)
Number of subjects: 213
Study 3291529 — intervention group
Group type: EXPERIMENTAL
Intervention: CQP 201‐403 at 0.005 mg daily
Number of subjects: 24
Study 3291529 — intervention group
Group type: EXPERIMENTAL
Intervention: CQP 201‐403 at 0.015 mg daily
Number of subjects: 24
Study 3291529 — intervention group
Group type: EXPERIMENTAL
Intervention: CQP 201‐403 at 0.025 mg daily
Number of subjects: 24
Study 3291529 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 1711753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of bleomycin sulphate (1 unit/ml)
Number of subjects: 36
Study 1711753 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 36
Study 71449 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 257
Study 71449 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin ('Trasylol')
Number of subjects: 257
Study 71449 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 257
Study 31523063 — intervention group
Group type: EXPERIMENTAL
Intervention: Early removal of silicone stents (2 weeks postoperatively)
Number of subjects: 50